In hepatic encephalopathy, when might a branched-chain amino acid (BCAA) enriched formula be used?

• A. For severe encephalopathy not responding to aggressive medical therapy
• B. In all patients with hepatic encephalopathy
• C. Only if patient declines lactulose therapy
• D. Never used

Answer: (A)

In hepatic encephalopathy, branched-chain amino acid–enriched formulas are used as an adjunct rescue therapy when the encephalopathy is severe and not adequately controlled by aggressive medical treatment (such as lactulose, rifaximin) alone. The idea behind this approach is to correct the imbalance between amino acids that occurs in liver failure: BCAAs (valine, leucine, isoleucine) decrease in relative abundance while aromatic amino acids rise, and increasing BCAAs can help restore protein synthesis and reduce the brain uptake of neurotoxic aromatic amino acids. This can support neurologic improvement in patients who are not responding to standard therapy and are often malnourished or catabolic. It’s not used routinely in all patients with hepatic encephalopathy, nor is it a sole replacement for first-line therapy, and it’s not specifically only indicated if a patient declines lactulose. Therefore, the best scenario is severe encephalopathy not responding to aggressive medical therapy.